Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 15;11(22):3613. doi: 10.3390/cells11223613

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Sorafenib treatment does seemingly not affect protein expression of epithelial markers and proliferation marker SOX9 in iCCAOs. (A) iCCAOs were treated for 48 h as indicated either with the vehicle control (DMSO 0.02%), or with 4 µM sorafenib, resp. Fluorescent immunohistochemistry revealed apical and basolateral expression of ZO-1 (green) and E-cadherin (red), resp. Nuclei are labeled with DAPI (blue). Insets show digital magnifications (orig. magnification: 20×) of selected areas of the pictures behind. Arrows indicate luminal expression of ZO-1. (B) iCCAOs were treated for 48 h as indicated. Fluorescent immunohistochemistry showed membranous expression of EpCAM (green). Nuclei are labeled with DAPI (blue). (C) iCCAOs were treated for 48 h as indicated. Fluorescent immunohistochemistry revealed apical expression of MDR1 (green, white arrows). (D) iCCAOs were treated for 96 h as indicated. SOX9 expression was localized in the nuclei (insets, black arrows in digital magnifications (orig. magnification: 10×) of selected areas of the pictures behind) as shown by non-fluorescent immunohistochemistry.